Đang chuẩn bị liên kết để tải về tài liệu:
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Despite reported discordance between the mutational status of primary lung cancers and their metastases, metastatic sites are rarely biopsied and targeted therapy is guided by genetic biomarkers detected in the primary tumor. This situation is mostly explained by the apparent stability of EGFR-activating mutations. |

TÀI LIỆU LIÊN QUAN

Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases

Báo cáo hóa học: "TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status"

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: Implications for translational research

Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.